X4 Pharmaceuticals stock
XFORNASDAQX4 Pharmaceuticals, Inc., HealthcareISIN US98420X2027
37Score 37 out of 100, Weak
Price and trend
54 / 100
Price history
−18% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 16% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 32% below its 52-week high. Largest decline in 9 years: 100% (March 2018 to August 2025).
Chart figures for advanced users
- SMA 50$3.17
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.78
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.45
- The lowest closing price of the last twelve months.
- Resistance$4.67
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- X4 Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $401.08M, is number 261 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $35.11M (up 1,273.2% year on year) and a loss of $79.2M.
- For fiscal 2026, analysts expect on average revenue of $17.12M (down 51.2%) and adjusted earnings per share of −$0.64.
Show more
- MEQIRI Score 37 out of 100 (Weak): rank 587 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $187.7M, financial debt $77.2M.
Weaknesses
- Loss-makingLoss of $80.52M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$95.7M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 72% a year over the last 12 months.Stability 49
The score is held back by capital allocation and fundamentals.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue rose 63.1% on the same quarter a year earlier. Revenue has grown strongly since 2024, at around 1273% per year. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 82%, operating −247%, net −226%. Last 12 months: net −100%. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 16 Mar 2027in 123 days
- Last reported
- 4 Nov 2026EPS reported −$0.16 (expected −$0.17)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 7.4% since 27 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.64+2.1%
- Revenue
- $17.12M+7.1%
- Earnings per share
- −$0.76−7.4%
- Revenue
- $12.32M+6.6%
MEQIRI has stored the estimates since 27 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $11,884 in total. 3 insiders sold, $390,144 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at X4 Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Puma BiotechnologyPBYI $417.72M61
- Tectonic TherapeuticTECX $411.32M33
- Assembly BiosciencesASMB $410.88M34
- RezoluteRZLT $405.49M37
- ProKidneyPROK $386.69M27
- Lyell ImmunopharmaLYEL $384.52M33
- ARS PharmaceuticalsSPRY $383.01M33
- Fennec PharmaceuticalsFENC $382.23M56
ETFs that hold X4 Pharmaceuticals
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.28B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2018)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.